Viridian Therapeutics (VRDN) financial statements
Viridian Therapeutics reported revenue of $71M in fiscal 2025, up 39.8% a year over 9 years.
Net income was -$343M and the operating margin -512.9%, against -488.6% in 2016.
Free cash flow was -$277M.
The diluted share count rose 7189% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Viridian Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3M | $4M | $8M | $4M | $1M | $3M | $2M | $314,000 | $302,000 | $71M |
| Cost of revenue | $3M | — | — | — | — | — | — | — | — | — |
| Gross profit | $929,000 | — | — | — | — | — | — | — | — | — |
| Research and development | $14M | $20M | $30M | $35M | $28M | $57M | $101M | $160M | $238M | $339M |
| Selling, general and admin | $8M | $11M | $11M | $12M | $13M | $26M | $35M | $95M | $61M | $95M |
| Operating income | -$17M | -$27M | -$33M | -$42M | -$110M | -$80M | -$134M | -$254M | -$299M | -$363M |
| Interest expense | $95,000 | $383,000 | $873,000 | $835,000 | $508,000 | $3,000 | $486,000 | $1M | $2M | $5M |
| Income tax | — | — | — | — | — | — | — | — | — | $0 |
| Net income | -$17M | -$27M | -$33M | -$42M | -$111M | -$79M | -$130M | -$238M | -$270M | -$343M |
| EPS (diluted) | -$28.21 | -$1.38 | -$1.10 | -$20.04 | -$31.13 | -$6.66 | -$4.05 | -$5.31 | — | — |
| Diluted shares | 1M | 19M | 30M | 2M | 4M | 12M | 32M | 45M | — | — |
| Gross margin | 26.7% | — | — | — | — | — | — | — | — | — |
| Operating margin | -488.6% | -662.8% | -394.5% | -941.0% | -10512.4% | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Net margin | -496.8% | -662.3% | -390.0% | -938.6% | -10544.3% | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
Balance sheet
Fiscal years, from Viridian Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $22M | $47M | $62M | $27M | $128M | $197M | $425M | $477M | $718M | $875M |
| Receivables | $20,000 | $1M | $24,000 | $108,000 | — | — | — | — | — | — |
| Inventory | $64,000 | — | — | — | — | — | — | — | — | — |
| Total current assets | $24M | $52M | $65M | $30M | $130M | $200M | $431M | $486M | $738M | $894M |
| Property, plant and equipment | $625,000 | $563,000 | $727,000 | $523,000 | $309,000 | $375,000 | $1M | $2M | $1M | $1M |
| Total assets | $25M | $52M | $66M | $30M | $131M | $204M | $435M | $490M | $742M | $899M |
| Total current liabilities | $7M | $4M | $7M | $10M | $11M | $14M | $33M | $27M | $48M | $71M |
| Long-term debt | — | — | — | — | — | — | — | $20M | $21M | — |
| Total liabilities | $10M | $14M | $15M | $15M | $11M | $16M | $40M | $48M | $71M | $177M |
| Shareholders' equity | -$62M | $39M | $51M | $16M | $120M | $188M | $395M | $442M | $672M | $722M |
| Net debt | -$22M | -$47M | -$33M | -$25M | -$46M | -$42M | -$156M | -$83M | -$79M | -$212M |
Cash flow
Fiscal years, from Viridian Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15M | -$28M | -$27M | -$36M | -$30M | -$55M | -$94M | -$184M | -$232M | -$276M |
| Capital spending | $250,000 | $246,000 | $445,000 | $84,000 | $42,000 | $338,000 | $797,000 | $898,000 | $511,000 | $495,000 |
| Free cash flow | -$15M | -$28M | -$27M | -$36M | -$30M | -$55M | -$95M | -$185M | -$233M | -$277M |
| Stock-based compensation | $198,000 | $2M | $4M | $4M | $4M | $14M | $20M | $67M | $42M | $44M |
| Share buybacks (net) | -$2,000 | — | — | — | — | — | — | — | — | — |
| Net borrowing | — | — | — | — | — | — | $5M | $15M | $0 | $29M |
| Free cash flow margin | -431.6% | -709.8% | -325.4% | -810.1% | -2840.1% | -1853.5% | -5340.6% | -58938.9% | -77096.0% | -390.8% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for VRDN.
Open VRDN in InvestinglyQuestions
What was Viridian Therapeutics's revenue in 2025?
$71M in fiscal 2025, from its 10-K filing.
How much free cash flow does Viridian Therapeutics generate?
-$277M in fiscal 2025 (operating cash flow minus capital spending).
From Viridian Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.